- Home
- RILYP vs GALT Comparison
RILYP vs GALT Comparison
Compare RILYP & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RILYP
- GALT
- Stock Information
- Founded
- RILYP 1973
- GALT 2000
- Country
- RILYP United States
- GALT United States
- Employees
- RILYP N/A
- GALT N/A
- Industry
- RILYP Investment Managers
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- RILYP Finance
- GALT Health Care
- Exchange
- RILYP Nasdaq
- GALT Nasdaq
- Market Cap
- RILYP N/A
- GALT 83.5M
- IPO Year
- RILYP N/A
- GALT N/A
- Fundamental
- Price
- RILYP $5.75
- GALT $2.79
- Analyst Decision
- RILYP
- GALT Buy
- Analyst Count
- RILYP 0
- GALT 2
- Target Price
- RILYP N/A
- GALT $6.00
- AVG Volume (30 Days)
- RILYP 34.3K
- GALT 664.5K
- Earning Date
- RILYP 01-01-0001
- GALT 08-12-2025
- Dividend Yield
- RILYP 14.85%
- GALT N/A
- EPS Growth
- RILYP N/A
- GALT N/A
- EPS
- RILYP N/A
- GALT N/A
- Revenue
- RILYP $854,383,000.00
- GALT N/A
- Revenue This Year
- RILYP N/A
- GALT N/A
- Revenue Next Year
- RILYP N/A
- GALT N/A
- P/E Ratio
- RILYP N/A
- GALT N/A
- Revenue Growth
- RILYP N/A
- GALT N/A
- 52 Week Low
- RILYP $1.73
- GALT $0.73
- 52 Week High
- RILYP $20.00
- GALT $3.90
- Technical
- Relative Strength Index (RSI)
- RILYP 84.29
- GALT 68.94
- Support Level
- RILYP $2.02
- GALT $2.77
- Resistance Level
- RILYP $6.18
- GALT $2.97
- Average True Range (ATR)
- RILYP 0.51
- GALT 0.20
- MACD
- RILYP 0.36
- GALT 0.04
- Stochastic Oscillator
- RILYP 94.74
- GALT 91.11
About RILYP B. Riley Financial Inc.
B. Riley Financial Inc is a diversified financial services company. The company through its subsidiaries offers investment banking and financial services to corporate, institutional, and high-net-worth clients and also asset disposition, valuation and appraisal, and capital advisory services to retail, wholesale, institutional, lenders, capital providers, private equity investors, and professional services firms in United States, Canada, and Europe. It also provides internet access and subscription services. The reportable operating segments of the company include Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications segment, and Consumer products segment.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.